Octopus Interim Decision announced!

The trial committees have reviewed the Octopus “checkpoint” data and the interim data decision has been released to Octopus participants, hospital sites, collaborators and the MS Community.  Alpha lipoic acid has shown sufficient evidence of benefit to proceed to the next stage of the trail. However metformin did not and so participants will be stopping this treatment and trial participation.

 

To see the results please view our news story on InCTU website and view our video explaining the results here.

 

FAQs are available on our AS decision point FAQ page  and further information is also available through the MS Society website.